An International, Seamless Phase II/III Responsive Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GBM AGILE)(Brain Tumors)
Study to Evaluate Multiple Treatments for Patients with Newly Diagnosed or Recurrent GBM
Sponsor: Global Coalition for Adaptive Research
Enrolling: Male and Female Patients
IRB Number: AAAS2589
U.S. Govt. ID: NCT03970447
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to evaluate multiple investigational treatments for either newly diagnosed or recurrent brain tumors to determine if any of these study treatment(s) improve overall survival as compared to standard treatments. Investigational means that these are new treatments sometimes called study drugs and are not approved by the Food and Drug Administration (FDA) to be used for your type of cancer. The investigational treatments in this study have been previously tested in people.
Andrew Lassman, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a newly diagnosed or recurrent glioblastoma? Yes No
Are you willing and able to provide written informed consent and to comply with the study protocol? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator